Studies in monogenic forms of IBD suggest that IL-1R1 blockade can resolve intestinal inflammation in patients with IL-10 receptor defects,52 mevalonate kinase defects and potentially gain-of-function NLRC453 defects, which are all characterised by increased inflammasome activation and IL-1 secretion. Here, IL1A is linked to inflammatory bowel disease.